DormaTarg, Inc.

DormaTarg is developing DT330, one of three synthetic anticancer drugs that inhibit recurrence in metastasis prone cancers, like triple negative breast cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Oklahoma City, OK, US
  • Currency USD
  • Founded April 2007
  • Employees 5
  • Website dormatarg.com

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free